Exploring the Brain, One Neuron at a Time

A repurposed spinal cord injury drug called KCL-286 tackles Alzheimer's from multiple angles by repairing DNA damage and reducing inflammation simultaneously. Having already passed initial human safety trials, it's poised to enter clinical testing faster than conventional single-target approaches, offering hope for a disease where current treatments remain limited.

Sugar-coated nanoparticles have successfully delivered tumor-suppressing genes through the blood-brain barrier to attack glioblastoma, the deadliest brain cancer. In mice, this innovative approach increased survival by 50% while shrinking tumors without harming healthy tissue, marking a major breakthrough against an otherwise intractable disease.

A common, inexpensive antidepressant called fluvoxamine significantly reduced debilitating fatigue in 399 long COVID patients during a clinical trial. This represents one of the first proven pharmaceutical interventions for a symptom that has plagued millions, offering real-world relief beyond supportive care.

Popular artificial sweeteners may accelerate cognitive aging by roughly 1.6 years, with the steepest declines appearing in people under 60 or those with diabetes. While researchers emphasize that cause-and-effect remains unproven, the findings challenge the assumption that sugar substitutes are a risk-free swap for the real thing.